

# Integrin Beta 3 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/I042A745121AEN.html>

Date: August 2019

Pages: 74

Price: US\$ 3,500.00 (Single User License)

ID: I042A745121AEN

## Abstracts

Integrin Beta 3 - Pipeline Review, H2 2019

### SUMMARY

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (?3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease, Central Nervous System and Immunology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Breast Cancer, Coronary Artery Disease (CAD) (Ischemic Heart

Disease), Diabetic Macular Edema, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Nephropathy, Diabetic Retinopathy, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Relapsing Multiple Sclerosis (RMS), Rheumatoid Arthritis, Sepsis, Staphylococcus Aureus Septicaemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

BrightGene Bio-Medical Technology Co Ltd

Celltrion Inc

Factor Therapeutics Ltd

Merck & Co Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Virtual Drug Development Inc

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles

A-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-0222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize ITGA5 and ITGB3 for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOD-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-1177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug  
Profile

Product Description

Mechanism Of Action

R&D Progress

rHlgM-22 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RUC-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

xemilofiban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones

Featured News & Press Releases

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Acorda Therapeutics Inc, H2 2019  
Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2019  
Pipeline by Celltrion Inc, H2 2019  
Pipeline by Factor Therapeutics Ltd, H2 2019  
Pipeline by Merck & Co Inc, H2 2019  
Pipeline by Pliant Therapeutics Inc, H2 2019  
Pipeline by SciFluor Life Sciences LLC, H2 2019  
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019  
Pipeline by Virtual Drug Development Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Mechanism of Actions, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Molecule Types, H2 2019  
Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Acorda Therapeutics Inc  
BrightGene Bio-Medical Technology Co Ltd  
Celltrion Inc  
Factor Therapeutics Ltd  
Merck & Co Inc  
Pliant Therapeutics Inc  
SciFluor Life Sciences LLC  
Tasly Pharmaceutical Group Co Ltd  
Virtual Drug Development Inc

## I would like to order

Product name: Integrin Beta 3 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/I042A745121AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I042A745121AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970